344 related articles for article (PubMed ID: 22775210)
1. Characterization of efflux transport of the PDE5 inhibitors, vardenafil and sildenafil.
Choi MK; Song IS
J Pharm Pharmacol; 2012 Aug; 64(8):1074-83. PubMed ID: 22775210
[TBL] [Abstract][Full Text] [Related]
2. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
Dahan A; Amidon GL
Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G371-7. PubMed ID: 19541926
[TBL] [Abstract][Full Text] [Related]
3. The role of efflux transporters on the transport of highly toxic aconitine, mesaconitine, hypaconitine, and their hydrolysates, as determined in cultured Caco-2 and transfected MDCKII cells.
Ye L; Yang X; Yang Z; Gao S; Yin T; Liu W; Wang F; Hu M; Liu Z
Toxicol Lett; 2013 Feb; 216(2-3):86-99. PubMed ID: 23200901
[TBL] [Abstract][Full Text] [Related]
4. Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2.
Mease K; Sane R; Podila L; Taub ME
J Pharm Sci; 2012 May; 101(5):1888-97. PubMed ID: 22359351
[TBL] [Abstract][Full Text] [Related]
5. Formation and efflux of ATP-binding cassette transporter substrate 2,4-dinitrophenyl-S-glutathione from cultured human term placental villous tissue fragments.
Vaidya SS; Walsh SW; Gerk PM
Mol Pharm; 2009; 6(6):1689-702. PubMed ID: 19397308
[TBL] [Abstract][Full Text] [Related]
6. The role of P-glycoprotein in intestinal transport versus the BBB transport of tetraphenylphosphonium.
Swed A; Eyal S; Madar I; Zohar-Kontante H; Weiss L; Hoffman A
Mol Pharm; 2009; 6(6):1883-90. PubMed ID: 19722701
[TBL] [Abstract][Full Text] [Related]
7. Aristolochic acid I is a substrate of BCRP but not P-glycoprotein or MRP2.
Ma L; Qin Y; Shen Z; Bi H; Hu H; Huang M; Zhou H; Yu L; Jiang H; Zeng S
J Ethnopharmacol; 2015 Aug; 172():430-5. PubMed ID: 26183576
[TBL] [Abstract][Full Text] [Related]
8. Interaction Studies of Resolvin E1 Analog (RX-10045) with Efflux Transporters.
Cholkar K; Trinh HM; Vadlapudi AD; Wang Z; Pal D; Mitra AK
J Ocul Pharmacol Ther; 2015 May; 31(4):248-55. PubMed ID: 25844889
[TBL] [Abstract][Full Text] [Related]
9. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib.
Graber-Maier A; Gutmann H; Drewe J
Mol Pharm; 2010 Oct; 7(5):1618-28. PubMed ID: 20701289
[TBL] [Abstract][Full Text] [Related]
10. An in vitro and in silico study on the flavonoid-mediated modulation of the transport of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) through Caco-2 monolayers.
Schutte ME; Freidig AP; van de Sandt JJ; Alink GM; Rietjens IM; Groten JP
Toxicol Appl Pharmacol; 2006 Dec; 217(2):204-15. PubMed ID: 16997339
[TBL] [Abstract][Full Text] [Related]
11. PDE5 inhibitors, sildenafil and vardenafil, reverse multidrug resistance by inhibiting the efflux function of multidrug resistance protein 7 (ATP-binding Cassette C10) transporter.
Chen JJ; Sun YL; Tiwari AK; Xiao ZJ; Sodani K; Yang DH; Vispute SG; Jiang WQ; Chen SD; Chen ZS
Cancer Sci; 2012 Aug; 103(8):1531-7. PubMed ID: 22578167
[TBL] [Abstract][Full Text] [Related]
12. Characterization of efflux transporters involved in distribution and disposition of apixaban.
Zhang D; He K; Herbst JJ; Kolb J; Shou W; Wang L; Balimane PV; Han YH; Gan J; Frost CE; Humphreys WG
Drug Metab Dispos; 2013 Apr; 41(4):827-35. PubMed ID: 23382458
[TBL] [Abstract][Full Text] [Related]
13. Glyceollin Effects on MRP2 and BCRP in Caco-2 Cells, and Implications for Metabolic and Transport Interactions.
Chimezie C; Ewing A; Schexnayder C; Bratton M; Glotser E; Skripnikova E; Sá P; Boué S; Stratford RE
J Pharm Sci; 2016 Feb; 105(2):972-981. PubMed ID: 26296158
[TBL] [Abstract][Full Text] [Related]
14. Presence or absence of a gallate moiety on catechins affects their cellular transport.
Kadowaki M; Sugihara N; Tagashira T; Terao K; Furuno K
J Pharm Pharmacol; 2008 Sep; 60(9):1189-95. PubMed ID: 18718123
[TBL] [Abstract][Full Text] [Related]
15. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
Yamada A; Maeda K; Kamiyama E; Sugiyama D; Kondo T; Shiroyanagi Y; Nakazawa H; Okano T; Adachi M; Schuetz JD; Adachi Y; Hu Z; Kusuhara H; Sugiyama Y
Drug Metab Dispos; 2007 Dec; 35(12):2166-76. PubMed ID: 17823233
[TBL] [Abstract][Full Text] [Related]
16. Zinc finger nuclease-mediated gene knockout results in loss of transport activity for P-glycoprotein, BCRP, and MRP2 in Caco-2 cells.
Sampson KE; Brinker A; Pratt J; Venkatraman N; Xiao Y; Blasberg J; Steiner T; Bourner M; Thompson DC
Drug Metab Dispos; 2015 Feb; 43(2):199-207. PubMed ID: 25388687
[TBL] [Abstract][Full Text] [Related]
17. Application and limitation of inhibitors in drug-transporter interactions studies.
Wang Q; Strab R; Kardos P; Ferguson C; Li J; Owen A; Hidalgo IJ
Int J Pharm; 2008 May; 356(1-2):12-8. PubMed ID: 18272304
[TBL] [Abstract][Full Text] [Related]
18. Intestinal absorption mechanism of mirabegron, a potent and selective β₃-adrenoceptor agonist: involvement of human efflux and/or influx transport systems.
Takusagawa S; Ushigome F; Nemoto H; Takahashi Y; Li Q; Kerbusch V; Miyashita A; Iwatsubo T; Usui T
Mol Pharm; 2013 May; 10(5):1783-94. PubMed ID: 23560393
[TBL] [Abstract][Full Text] [Related]
19. Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters.
Weiss J; Sauer A; Divac N; Herzog M; Schwedhelm E; Böger RH; Haefeli WE; Benndorf RA
Biopharm Drug Dispos; 2010 Mar; 31(2-3):150-61. PubMed ID: 20222053
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of intestinal absorption of amtolmetin guacyl in rats: breast cancer resistant protein as a primary barrier of oral bioavailability.
Rong Z; Xu Y; Zhang C; Xiang D; Li X; Liu D
Life Sci; 2013 Feb; 92(3):245-51. PubMed ID: 23333829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]